POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.645 EUR | +8.22% |
|
-4.16% | +17.06% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.42M | Sales 2022 | 674K 725K | Capitalization | 27.16M 29.23M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.75M | Net income 2022 | -31M -33.36M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.23M | Net Debt 2022 | 32.74M 35.23M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
More news
| 1 day | +8.22% | ||
| 1 week | -4.16% | ||
| Current month | +5.74% | ||
| 1 month | +9.69% | ||
| 3 months | +38.12% | ||
| 6 months | +68.41% | ||
| Current year | +17.06% |
1 week
0.57
0.71
1 month
0.570.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.645 | +8.22% | 574,184 |
| 24-05-02 | 0.596 | -2.30% | 376,191 |
| 24-04-30 | 0.61 | -8.27% | 634,015 |
| 24-04-29 | 0.665 | -1.19% | 441,032 |
| 24-04-26 | 0.673 | +1.97% | 495,428 |
Real-time Euronext Paris, May 03, 2024 at 11:35 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +17.06% | 26.93M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- POXEL Stock
